Glucagon-Like Peptide-1 Receptor
-
Subject Areas on Research
- Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake.
- Authors' reply to "Comment on generalizability of GLP-1 RA CVOTs in US T2D population".
- Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
- Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.
- CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors.
- Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
- Central Nervous System GLP-1 Receptors Regulate Islet Hormone Secretion and Glucose Homeostasis in Male Rats.
- Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem.
- DREADDing proglucagon neurons: a fresh look at metabolic regulation by the brain.
- Deletion of the glucagon receptor gene before and after experimental diabetes reveals differential protection from hyperglycemia.
- Disruption of Glucagon-Like Peptide 1 Signaling in Sim1 Neurons Reduces Physiological and Behavioral Reactivity to Acute and Chronic Stress.
- Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism.
- Effect of GLP-2 on mucosal morphology and SGLT1 expression in tissue-engineered neointestine.
- Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease.
- Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.
- Enhanced Glucose Control Following Vertical Sleeve Gastrectomy Does Not Require a β-Cell Glucagon-Like Peptide 1 Receptor.
- Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans.
- GLP-1 and energy balance: an integrated model of short-term and long-term control.
- GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.
- GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats.
- GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats.
- Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.
- Genetically Encoded Cholesterol-Modified Polypeptides.
- Give the receptor a brake: slowing gastric emptying by GLP-1.
- Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).
- Glucagon-like peptide 1: continued advances, new targets and expanding promise as a model therapeutic.
- Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.
- Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis.
- Gut peptides in the treatment of diabetes mellitus.
- High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.
- Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus.
- Interaction of GLP-1 and Ghrelin on Glucose Tolerance in Healthy Humans.
- Is GLP-1 a hormone: Whether and When?
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
- Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility.
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
- Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect.
- New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?
- Oral L-arginine stimulates GLP-1 secretion to improve glucose tolerance in male mice.
- Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists.
- Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.
- Risk vs benefit in diabetes pharmacotherapy: a rational approach to choosing pharmacotherapy in type 2 diabetes.
- Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists.
- Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.
- Targeted gene disruption in endocrine research--the case of glucagon-like peptide-1 and neuroendocrine function.
- Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes.
- The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice.
- The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness.
- The effects of GLP-1 infusion in the hepatic portal region on food intake.
- The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis.
- The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes.
- The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride.
- The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs.
- Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
- Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.
- What if gut hormones aren't really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tract.